Analyst Scoreboard: 5 Ratings For Health Catalyst
Portfolio Pulse from Benzinga Insights
Health Catalyst (NASDAQ:HCAT) has received mixed analyst ratings over the last three months, with 2 bullish and 3 somewhat bullish ratings. The average 12-month price target for HCAT has been raised to $11.8, up from $11.50. Analysts from Canaccord Genuity, Guggenheim, Evercore ISI Group, Piper Sandler, and JP Morgan have adjusted their ratings and price targets, reflecting diverse perspectives on the company's performance and market position. Health Catalyst's financial health indicators such as market capitalization, revenue growth, net margin, ROE, ROA, and debt management are also highlighted, showcasing the company's strengths and areas of concern.
February 23, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Health Catalyst has seen a mix of bullish and somewhat bullish ratings from analysts, with an updated average 12-month price target of $11.8. Financial health indicators such as revenue growth and net margin are positive, while the company's market capitalization and debt management reflect areas of concern.
The mixed analyst ratings with an upward revision in the average price target suggest a cautiously optimistic outlook for HCAT. Positive financial indicators like revenue growth and net margin support a potential short-term positive impact on the stock price. However, concerns about market capitalization and debt management could temper gains.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100